Chimerix (CMRX) said Monday it has submitted a new drug application with the US Food and Drug Administration for the accelerated approval of its experimental drug, dordaviprone, which is intended to treat a type of tumor caused by a mutation in the histone 3 gene.
The company said it has requested a priority review, which could lead to a decision by Q3 2025.
Chimerix also said it has entered an amended loan agreement with Silicon Valley Bank for up to $30 million.
The agreement allows the company to draw up to $20 million through February 2026, with an additional $10 million available upon approval through February 2027.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.